North American study and meta-analysis evaluating performance of Bladder EpiCheck®, a FDA cleared test, in non-muscle invasive bladder cancer recurrence [0.03%]
评估Bladder EpiCheck®（一种获得FDA批准的测试）在非肌层浸润性膀胱癌复发中的性能的北美研究和荟萃分析
Neil Fleshner,Herbert Barton Grossman,Ryan Berglund et al.
Neil Fleshner et al.
Background: Bladder EpiCheck (BE) is a novel methylation-based PCR urine test for the detection of non-muscle invasive bladder cancer (NMIBC) recurrences. ...
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis [0.03%]
膀胱癌的卡介苗治疗：通过基于人工智能的社会媒体分析探索患者体验和关注点
Zine-Eddine Khene,Isamu Tachibana,Raj Bhanvadia et al.
Zine-Eddine Khene et al.
Background: There is a notable disparity between the guidelines for BCG therapy in non-muscle invasive bladder cancer (NMIBC). Reddit has emerged as a popular online platform for individuals seeking information and exchan...
Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis [0.03%]
抗血管生成治疗联合免疫检查点阻断在尿路上皮癌中的应用：系统回顾与荟萃分析
Mohammad Jad Moussa,Iuliia Kovalenko,Emanuele Crupi et al.
Mohammad Jad Moussa et al.
Background: Antiangiogenic therapy had been tested in urothelial cancer (UC) without reaching the clinic. Objective: We provide a syste...
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives [0.03%]
膀胱癌中单细胞RNA测序和空间转录组学分析：现状与未来展望
Kentaro Yoshihara,Kagenori Ito,Takahiro Kimura et al.
Kentaro Yoshihara et al.
Background: Bladder cancer is one of the most prevalent malignancies, and the mechanisms underlying its progression and the role of the tumor microenvironment (TME) are unclear. Recent advancements in single-cell RNA sequ...
Management of bladder cancer in kidney transplant recipients: A narrative review [0.03%]
肾移植受者膀胱癌的治疗：一项记叙性回顾
Khi Yung Fong,Ee Jean Lim,Wei Zheng So et al.
Khi Yung Fong et al.
Background: Bladder cancer in the setting of previous a kidney transplant (KT) is challenging to manage due to complex medical and surgical considerations. ...
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer [0.03%]
NCI临床试验计划会议关于非肌层浸润性膀胱癌新一代临床试验的摘要
Andrea Apolo,Brian C Baumann,Hikmat Al-Ahmadie et al.
Andrea Apolo et al.
The National Cancer Institute organized a virtual Clinical Trials Planning Meeting (CTPM) on 'Defining the next generation of clinical trials with combination therapies in non-muscle invasive bladder cancer (NMIBC)' led by the Bladder Cance...
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer [0.03%]
DNA修复缺陷对膀胱癌中抗体药物偶联物(ADC)负载敏感性的影响研究
Surish P Shanmugam,Yuzhen Zhou,Isabella Stelter et al.
Surish P Shanmugam et al.
Background: Enfortumab vedotin (EV) and Sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) with demonstrated activity in advanced bladder cancer. A subset of bladder tumors harbors a DNA repair deficiency in e...
Practice patterns and outcomes of conventional versus split-dose cisplatin in neoadjuvant ddMVAC in bladder cancer [0.03%]
膀胱癌新辅助ddMVAC化疗中传统顺铂与分次顺铂的用药模式及预后
Eryn B Callihan,Elizabeth Molina Kuna,Corbin J Eule et al.
Eryn B Callihan et al.
Background: The practice patterns and efficacy of ddMVAC administered with split-dose cisplatin for patients with muscle-invasive bladder cancer (MIBC) remains largely undefined. ...
Edward M Messing
Edward M Messing
Mark S Soloway,Neil A Abrahams,Nat Pinnar
Mark S Soloway